Patterns of disease progression (PD) and efficacy associated with tumour burden from the phase III IMforte study of lurbinectedin (lurbi) plus atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in ES-SCLC

Paz-Ares L., Borghaei H., Liu S. V., Peters S., Herbst R. S., Kazarnowicz A., ...More

ANNALS OF ONCOLOGY, vol.36, 2025 (SCI-Expanded, Scopus)

• Publication Type: Article / Abstract
• Volume: 36
• Publication Date: 2025
• Doi Number: 10.1016/ja0c2023:085372
• Journal Name: ANNALS OF ONCOLOGY
• Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
• Kocaeli University Affiliated: Yes